What is the general market price of a box of ruxolitinib tablets/ruxolitinib in 2025?

Ruxolitinib tablets/ruxolitinib (JAKAVI), as a small molecule inhibitor targeting the JAK1 and JAK2 signaling pathways, has been widely used in the treatment of a variety of hematological diseases. Its main indications include medium- and high-risk myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD). Its treatment ideas focus on the inflammation-driven nature of the disease and relieve symptoms and control disease progression by inhibiting abnormal signaling in the body. Globally, ruxolitinib has been listed as a first-line treatment option for related diseases in treatment guidelines in many countries.

In China, ruxolitinib tablets have been registered and officially launched, and have been included in the national medical insurance directory, providing patients with a certain degree of economic burden relief. However, the market price of the drug is still relatively high. Taking regular 5mg or 15mg tablets as an example, each box sells for about 3,000 yuan. The actual out-of-pocket portion varies depending on medical insurance policies and reimbursement ratios. The reimbursed price may vary in different cities. For specific circumstances, it is recommended to consult the local medical insurance bureau or hospital pharmacy for accurate information. This high cost still poses a burden for patients taking long-term medications, especially at higher doses or in combination therapies.

In contrast, the price of ruxolitinib in foreign markets also fluctuates to a certain extent. The price of the original drug in some countries such as Turkey is about RMBRMB 4,000, which remains at a relatively high level. The emergence of generic drugs has provided patients with more choices, especially the generic version of ruxolitinib produced by pharmaceutical companies in Laos and other places. Its ingredients are basically the same as the original drug. The specifications are usually 15mg*30 tablets, and the price is much more affordable, about more than 1,000 yuan. Although prices have been significantly reduced, the quality, efficacy, and stability of generic drugs still need to be evaluated through formal channels. It is recommended that patients avoid purchasing through unofficial channels to prevent buying counterfeit drugs or inferior products.

Reference materials:https://www.jakavi.com/